At the J.P. Morgan Healthcare Conference in San Francisco, the AI drug discovery pitch is familiar: shrink timelines, automate bottlenecks, take a process that spans a decade-plus and billions of dollars and compress it. For years, the industry has treated speed and cost as the headline metrics. The numbers, however, still point in the wrong…
Insilico, newly listed in Hong Kong, strikes up to $888M oncology deal with Servier
Days after going public on the Hong Kong Stock Exchange, Insilico Medicine has struck a multi-year oncology drug discovery partnership with France’s Servier worth up to $888 million. The collaboration will focus on developing oncology therapies, by combining Insilico’s AI-driven drug discovery platforms with Servier’s global expertise in cancer drug development. Insilico pointed to its…